Captura Biopharma

Write a Review501-516-3905

Captura Biopharma is an biotechnology company engaged in the development and commercialization of heavy metal chelators useful in the treatment of internal radionuclide contamination and heavy metal poisoning. Its lead chelation candidate, C2E2, will be the world's first oral treatment indicated for internal radiation contamination and has been proven in efficacy studies to target select heavy metals, notably americium, plutonium, and lead. Heavy metal contamination, including exposure to transuranic elements, is on the rise.